Cornell Engineers Develop Nanoparticle Delivery System for Antibodies
Cornell engineers have made a groundbreaking advancement in the field of medicine by developing a novel delivery system that utilizes lipid nanoparticles to transport therapeutic antibodies into cells. This innovative approach has the potential to revolutionize the treatment of various diseases, including cancer, inflammation, and Parkinson's disease.
The research, published in the Proceedings of the National Academy of Sciences, showcases the remarkable ability of these lipid nanoparticles to smuggle antibodies into cells, where they can exert their therapeutic effects. The lead author, Azmain Alamgir, a postdoctoral researcher at MIT, collaborated with Chris Alabi and Matt DeLisa from Cornell's Duffield College of Engineering to develop this groundbreaking technology.
The initial technology, which was initially focused on intracellular delivery of biologics, involved cloaking proteins by remodeling their surfaces with a negatively charged ion. This allowed the proteins to electrostatically join with positively charged lipid nanoparticles, forming tiny bubbles of fat. Once inside the cells, the proteins uncloak and deliver their therapeutic impact.
The breakthrough was further enhanced by the collaboration with the Schroeder lab at the Technion-Israel Institute of Technology. They recognized the potential of the cloaking approach to deliver anti-alpha-synuclein antibodies into brain cells, targeting the driver of Parkinson's disease. This marked a significant milestone as it demonstrated the technology's effectiveness in a living system, independent of the researchers' location.
The Cornell team's cloaking technology, known as SL4, and the associated protocol were successfully applied to alpha-synuclein-specific antibodies, showcasing the technology's versatility. The researchers also designed their own clinical demonstration using commercial anti-NF-kB antibodies, targeting lung inflammation in a mouse model of acute lung injury.
What sets this research apart is the breadth of translational evidence generated. The team demonstrated the technology's effectiveness in two distinct clinical indications, one in the brain and one in the lungs, showcasing improved delivery and therapeutic benefits. This versatility is a significant advantage, as it opens up new possibilities for treating various diseases.
Looking ahead, the researchers are exploring alternative cloaking groups and have launched their own company, Cloak Bio, to explore additional therapeutic avenues. The potential of this technology to transform medicine is immense, and the team's enthusiasm and dedication to its development are inspiring. This breakthrough is a testament to the power of scientific collaboration and innovation, offering hope for improved treatments and a brighter future in healthcare.
